Market Cap (In SEK)
66.37 Million
Revenue (In SEK)
7.07 Million
Net Income (In SEK)
-45.89 Million
Avg. Volume
33.96 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 4.03-12.55
- PE
- -
- EPS
- -
- Beta Value
- 0.749
- ISIN
- SE0010868943
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Mr. Johan Waborg
- Employee Count
- -
- Website
- https://www.iconovo.se
- Ipo Date
- 2018-04-06
- Details
- Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
More Stocks
-
3388
-
600380
-
VEII
-
WTFC
-
1773
-
600036
-
4462
-
GISSAA